Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway

OBJECTIVES: Despite advances in the development of novel targeted therapies, the need for B-ALL alternative treatments has not been met. Anlotinib could blunt the proangiogenic activity of VEGFR, PDGFR, and FGFR, and has shown strong antitumor activities across multiple tumors. However, anlotinib cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qiuling, Lai, Qian, Jiang, Yuelong, Yao, jingwei, Chen, Qinwei, Zhang, Li, Wang, Caiyan, Zhou, Yong, Deng, Manman, Xu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418595/
https://www.ncbi.nlm.nih.gov/pubmed/35985203
http://dx.doi.org/10.1016/j.tranon.2022.101516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418595/
https://www.ncbi.nlm.nih.gov/pubmed/35985203
http://dx.doi.org/10.1016/j.tranon.2022.101516

Ejemplares similares